RARE ULTRAGENYX PHARMACEUTICAL IN
2026Q1 · CUSIP 90400D108 · Sector: Healthcare & Biotech
Neutral · No signal
Holders
293
Δ holders QoQ
+5
Breadth percentile
Top 43%
Whale holders
151
Δ whales
+7
Inst. holding value
$2.0B
New positions
62
Closed positions
57
Price momentum (1Q)
+19.9%
Put / Call
7/9
Breadth history (34 quarters)
Past Lit Events & Aftermath 8 lit events
| Period | Percentile | Next-1Q return | Next-2Q return |
|---|---|---|---|
| 2024Q3 | Top 11% | -2.7% | -18.9% |
| 2024Q1 | Top 8% | +28.4% | +6.9% |
| 2023Q2 | Top 19% | +3.2% | +24.6% |
| 2022Q3 | Top 11% | +38.3% | +41.7% |
| 2020Q4 | Top 12% | -23.6% | -39.0% |
| 2020Q3 | Top 17% | +20.5% | -8.5% |
| 2020Q2 | Top 18% | +33.9% | +63.4% |
| 2018Q3 | Top 10% | +9.4% | +9.9% |
Options Sentiment
Put holders
7
QoQ: -5
Call holders
9
QoQ: -13
See methodology →
Fundamentals
PE (TTM)
—
EPS (TTM)
$-6.10
EPS YoY
—
Revenue (TTM)
$0.7B
Revenue YoY
+13.5%
Quarterly Revenue & EPS (4Y)
Quarterly figures; EPS split-adjusted, early quarters hidden when not calibrable
As of 2026-03-31 · SEC filings (XBRL)